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Abstract  
Huntington’s disease (HD) is a representative polyglutamine (polyQ) disease caused by aberrant 
expansion of the polyQ tract in Huntingtin (Htt). While motor impairment mediated by 
polyQ-expanded Htt has been intensively studied, molecular mechanisms for non-motor 
symptoms such as psychiatric manifestations in HD remain elusive. Here we demonstrate that 
Htt forms a ternary protein complex with DISC1 and cAMP-degrading phosphodiesterase-4 
(PDE4), which regulates PDE4 activity. The pathogenic sequestration of amyloidogenic DISC1 
into mutant Htt aggregates by cross-seeding is observed in the brains of HD patients and those of 
the R6/2 model that represents the polyQ pathology of HD. Consequently, the R6/2 model shows 
a PDE4 fraction becoming out of physiological control by DISC1, aberrantly increasing the 
activity of PDE4. Importantly, exogenous expression of DISC1 that binds to PDE4, but not 
mutant Htt, normalizes PDE4 activity and ameliorates anxiety-like phenotypes in the R6/2 model. 
Together, we propose that cross-seeding of mutant Htt and DISC1 and resultant changes in 
PDE4 may underlie the pathology, in particular the mental manifestations, of HD.  
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Introduction 
Huntington’s disease (HD) is a hereditary brain disease characterized by both motor and 
non-motor manifestations. Identification of the causal gene for Huntington’s disease (HD), 
Huntingtin (Htt), has facilitated our understanding of the molecular pathways that mediate 
disease pathology. For instance, it has been demonstrated that functional and structural changes 
in mutant Htt elicited by the aberrant expansion of polyglutamine (polyQ) lead to the impairment 
of axonal transport and loss of medium spiny neurons. These deficits have been associated with 
motor dysfunction in HD (1-6). HD is also characterized by non-motor dysfunctions, such as 
depression and anxiety (7). Nonetheless, the molecular mechanisms underlying such mental 
manifestations in HD have not been well studied.  
One of the leading mediators for cellular signaling involving higher brain functions is 
cyclic 3’5’ adenosine monophosphate (cAMP) (8-10). cAMP levels are decreased in the 
cerebrospinal fluid from HD patients and in the brains from the HdhQ111 knock-in mouse model 
for HD (11, 12). cAMP is degraded by various phosphodiesterases of which members of the 
phosphodiesterase-4 (PDE4) family play a major role including underpinning compartmentalized 
cAMP signaling in cells (13). Active site-directed small molecule inhibitors specific for PDE4, 
such as rolipram, together with targeted gene knockout and genetic studies, have shown that 
PDE4 regulates a wide range of brain functions, in particular mental states such as depression 
and anxiety (14-18). The activity of PDE4 is physiologically regulated at various levels, 
including intracellular localization, protein interaction, and posttranslational modifications (13, 
18). One of the critical direct interactors with PDE4 is the intracellular scaffold protein DISC1 
(16, 19-21). Physiological roles for DISC1 in biological pathways in brain development and 
neuro-signaling have been intensively studied for the past decade in various animal models 
(22-24). Yet, the significance of the DISC1-PDE4 interaction in neuropathological conditions is 
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poorly understood. Identification of a DISC1-PDE4 complex in conjunction with dysregulation 
of cAMP in HD would suggest the possibility that Htt might be involved in the DISC1-PDE4 
pathway, but this mechanistic link has not been examined to date. Furthermore, DISC1 was 
previously shown to form insoluble aggregates (25, 26), but the structural basis of DISC1 
aggregation and its neuropathological effects have not been investigated. Here we address a 
novel molecular mechanism involving the disturbance of DISC1-PDE4 interactions and 
behavioral changes through aggregation of DISC1 in HD.  
 
Results 
Augmentation of PDE4 activity in the R6/2 mice representing polyQ pathology of HD.  We set 
out to determine a role for PDE4 in HD by first investigating its activity in R6/2 mouse model 
that is known to represents polyQ pathology of HD. Intriguingly, we observed a profound 
augmentation of PDE4 activity in both the cerebral cortex and striatum at 8 weeks (Figure 1A), 
prior to robust manifestation of motor dysfunction and intranuclear inclusions of Htt (27). 
Elevated PDE4 activity was also observed at up to 12 weeks of age (Figure 1A). These results 
may provide an explanation why rolipram has beneficial effects in the R6/2 model (28, 29). 
Consistent with our novel discovery in vivo, when we evaluated a cell model that stably 
expresses an N-terminal 1-67 amino acid fragment (corresponding to exon 1) of Htt with 
expanded polyQ (Htt67Q150) (30), we noted that PDE4 activity was increased by more than 
3-fold (Supplemental Figure 1). 
Regulation of PDE4 activity by a Htt-DISC1-PDE4 ternary protein complex.  DISC1 
interacts with dynactin (p150glued), nuclear receptor corepressor (N-CoR), pericentriolar 
material-1 protein (PCM1), and Kalirin-7, all of which also reportedly interact with 
huntingtin-associated protein 1 (HAP1) and/or Htt (22-24). The frequency of common binding 
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partners of DISC1 and Htt implied that these two proteins may interact either directly or 
indirectly. A recent bioinformatic approach also resulted in a similar proposal (31). As DISC1 
and PDE4 proteins interact physically and functionally (16, 19, 32), we hypothesized that 
DISC1-PDE4, PDE4-Htt, and Htt-DISC1 proteins might interact. To evaluate this hypothesis, we 
conducted co-immunoprecipitation with the homogenates of whole mouse brains and identified 
the DISC1-PDE4, PDE4-Htt, and Htt-DISC1 protein interactions. (Figures 1B and 
Supplemental Figure 2). The DISC1-Htt and DISC1-PDE4 binding was more significant in 
striatum and cerebral cortex than in cerebellum (Supplemental Figure 3A).  
Next, we asked whether these three proteins might form a ternary complex. Indeed, 
sequential co-immunoprecipitation demonstrated the formation of such a ternary complex 
(Figure 1C). PDE4B interacts with DISC1 in a unique manner (19), and has been implicated, 
from genetic association studies, to be an important DISC1 partner (16, 33). The PDE4B gene 
encodes several distinct isoforms of which the major ones are the PDE4B1 and PDE4B3 long 
forms and the PDE4B2 short form (34). We thus evaluated the binding of DISC1 with each of 
these isoforms and found that they each bound to DISC1 and to Htt. (Supplemental Figure 3, B 
and C). 
Specific effect of polyQ expansion on the protein binding of Htt with DISC1.  Given that 
PDE4, Htt, and DISC1 form a ternary protein complex, then how does polyQ expansion in Htt 
affect these protein interactions? We examined how the polyQ expansion affected Htt-DISC1 
protein interaction by using an N-terminal 1-513 amino acid fragment of Htt with 18 residues of 
polyQ, or pathologically expanded 82 residues of polyQ (designated Htt513Q18 and Htt513Q82, 
respectively). The Htt513 and DISC1 interaction was augmented more than 2-fold when polyQ 
was expanded (Figure 1D). The increased binding was also observed when a shorter N-terminal 
fragment with an equal polyQ expansion (Htt67Q82) was used together with DISC1 (Figure 1E). 
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However, the binding of DISC1 with Htt513 was greater than that with Htt67 (Supplemental 
Figure 4A). These results indicate that amino acids 1-67 of Htt are sufficient to interact with 
DISC1, but that additional amino acids between 68 and 513 further facilitate the interaction. The 
effect of expanded polyQ on Htt-DISC1 binding was not observed in the interaction between 
PDE4B and Htt513 (Supplemental Figure 4B), implying that the polyQ expansion  
has unique pathophysiological effects on the Htt-DISC1 interaction. 
Selective sequestration of DISC1 into SDS-insoluble Htt aggregates in the R6/2 mice and 
HD’s brains.  One of the hallmarks of HD is the formation of SDS-resistant 
aggregates/inclusions of mutant Htt with expanded polyQ (35). DISC1 is also reportedly prone to 
aggregation (25, 26), but its pathophysiological significance is, as yet, unclear. Thus, we tested 
whether a pool of DISC1 could be detected in the SDS-resistant fraction of the brains from the 
R6/2 model, as well as HD patients, by using a filter trap assay. Significant increases in the 
levels of DISC1 in the SDS-resistant fractions from the cerebral cortex and striatum of R6/2 
mice were observed, compared with those of normal mice (Figure 2A). Similar results were 
observed in the SDS-insoluble fractions from HD patients compared with those from normal 
controls (Figure 2B). In contrast, we did not find PDE4B immunoreactivity in the SDS-resistant 
fractions of any brain samples. Furthermore, by western blotting, we observed immunoreactivity 
of DISC1, but not that of PDE4B, on the top of the gel when we applied brain homogenates from 
R6/2 mice (Supplemental Figure 5A), further supporting the notion that a pool of DISC1 is 
insoluble to SDS in the R6/2 brain.  
To test whether this insoluble DISC1 is associated with mutant Htt aggregation, we 
examined immunofluorescent tissue staining. We found that high-intensity DISC1 staining was 
co-localized with intranuclear aggregates of mutant Htt in both the cerebral cortex and striatum 
of R6/2 mice (Figure 2C). Furthermore, co-localization of DISC1 in the Htt aggregates was also 
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observed in the sections from the cortex and striatum of HD patients (Figure 2D). In contrast, no 
co-localization of PDE4B in Htt aggregates was detected in R6/2 mouse brains (Supplemental 
Figure 5B). 
Cross-seeding between intrinsically amyloidogenic DISC1 and polyQ-expanded mutant Htt.  
The above results suggested that pathologically enhanced interaction of DISC1 and mutant Htt 
may selectively facilitate the sequestration of DISC1into the Htt aggregates. Therefore, we set 
out to evaluate possible biophysical mechanisms underlying the selective aggregation of DISC1 
in HD. First, we aimed to reveal structural and physical properties of full-length DISC1 
aggregates, which have not yet been fully characterized even though DISC1 has been shown to 
be aggregation-prone in nature (25, 26). We performed multiple biophysical assays in vitro and 
found that DISC1 formed amyloid fibers and that DISC1 aggregates reacted to an 
amyloid-specific dye, thioflavin T, at a level comparable to the typical amyloid, Htt67Q42 (35) 
(Figure 3A). The fibrillar morphology was confirmed by electron microscopy (Figure 3B). 
Furthermore, circular dichroism spectra of DISC1 aggregates showed a negative peak at 228 nm, 
indicating amyloid-like β-sheet-rich structures (36) (Supplemental Figure 6). These data show 
that DISC1 can form amyloid-like aggregates in vitro. As DISC1 does not contain 
glutamine/asparagine-rich domains that could induce aggregation, we examined a core region of 
DISC1 aggregates by mass spectrometry. Limited proteolysis of DISC1 aggregates with 
proteinase K treatment followed by MALDI-TOF mass analysis showed a single major peak at 
2012.9 (m/Z) in the mass spectrum, which identified the core of DISC1 aggregates as the region 
consisting of residues 209-227 (Figure 3C).  
We then examined the effects of Htt aggregates on the kinetics of DISC1 aggregation. As 
expected from the amyloidogenicity, DISC1 spontaneously formed aggregates, but the 
aggregation was not evident for the initial 2 h under the conditions tested. This 2 h lag time was 
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almost completely abolished by the addition of seeds (10% mol/mol) of DISC1 aggregates at the 
initiation of the reaction, indicating that DISC1 aggregates are self-propagating, a key feature of 
amyloidogenicity (37-39) (Figure 3D). More importantly, DISC1 aggregation was significantly 
accelerated with the addition of seeds of Htt67Q42 aggregates, but not with the addition of BSA 
aggregates, which were employed as a control (Figure 3D). These data reveal cross-seeding 
between DISC1 and mutant Htt, which is consistent with the marked co-localization of the two 
proteins in HD brains in vivo (Figure 2D).  
The DISC1 aggregates that formed with seeds of Htt67Q42 aggregates showed an increase 
in the peak at 1620 cm-1 in Fourier-transform infrared (FT-IR) spectra, indicating a greater level 
of intermolecular β-sheet structures, compared to the DISC1 aggregates that were spontaneously 
formed in the absence of seeds (Figure 3E). Consistently, we found that the DISC1 aggregates 
formed with seeds of Htt67Q42 aggregates showed higher resistance to 2% SDS than did 
spontaneously formed DISC1 aggregates (Figure 3F). The altered structural and physical 
properties of the DISC1 aggregates also supported the cross-seeding between DISC1 and mutant 
Htt. 
Reduced DISC1-PDE4 interactions by decreased soluble DISC1 levels in the R6/2 Mice.  
We then asked whether the physiological disposition of DISC1 might be impaired because of the 
selective sequestration of this protein into the Htt aggregates in HD pathology. First, we 
employed sedimentation analysis with homogenates of the cerebral cortex and striatum, and 
observed that the level of soluble DISC1, but not that of PDE4B, was reduced in R6/2 mice 
compared to that in wild-type mice (Figure 4A). DISC1 interacts with PDE4B in soluble 
fractions and regulates the enzymatic activity of PDE4 (16, 32). Thus, reduction in the levels of 
soluble DISC1 may result in a decrease in physiological DISC1-PDE4 interaction. In mouse 
brain homogenates, we showed a significant reduction of DISC1-PDE4 interaction in R6/2 
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compared with that in wild-type mice (Figure 4B). Furthermore, we addressed whether the 
reduction of DISC1-PDE4B interaction was elicited directly by the presence of mutant Htt. We 
added lysates of cells overexpressing Htt513Q18 or Htt513Q82 to cell lysates in which DISC1 
and PDE4B interact, and examined how exogenous Htt513 proteins impact the DISC1-PDE4B 
binding. The addition of Htt513Q82 resulted in a significant reduction of pre-existing 
DISC1-PDE4B interactions, whereas that of Htt513Q18 did not (Figure 4C). Notably, as 
described above, augmented binding of Htt to DISC1 was observed with Htt513Q82 compared 
with Htt513Q18 (Figure 1D). Thus, a relative loss of DISC1’s interaction with PDE4 is likely a 
major effect of the DISC1 sequestration into Htt aggregates due to the preferred binding of 
DISC1 with polyQ-expanded mutant Htt.  
Htt-DISC1-PDE4 interactions for aberrant enhanced PDE4 activity in R6/2 mice. 
We propose that sequestration of DISC1 into HD aggregates may disturb the regulatory effects 
of DISC1 on PDE4, resulting in aberrant augmentation of PDE4 enzymatic activity, which 
contributes to HD pathology. If this scenario is correct, supplementing wild-type DISC1 might 
ameliorate such increase of PDE4 activity in the models we have studied here. As described 
above, the overexpression of Htt67Q150 in neuro2a cells, in which substantial levels of 
endogenous DISC1 were expressed, (40) augmented PDE4 activity by 3- to 4-fold 
(Supplemental Figure 1). When we exogenously overexpressed wild-type DISC1 in the 
neuro2a cells carrying Htt67Q150, the aberrant augmentation of PDE4 activity was significantly 
ameliorated (Supplemental Figure 7A). Although these results are promising in terms of 
protecting cells against pathological PDE4 activation, we were curious why the beneficial effects 
of exogenous DISC1 were only partial. This may be because exogenously expressed DISC1 was 
also, at least in part, sequestered into Htt aggregates and could not fully regulate endogenous 
PDE4 activity.  
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We then set out to identify the region of DISC1 responsible for Htt binding, using a peptide 
array approach that has been used to successfully map the binding domain of DISC1 with protein 
interactors and PDE4 with various partner proteins (18, 19). We anticipated that a mutant DISC1 
lacking a minimal domain for Htt interaction but maintaining PDE4 binding would not be 
sequestered into the Htt aggregates and thus would fully regulate PDE4 activity. Analyses of 
mouse and human DISC1 led to consistent results conserved between the two species, in which 
amino acids 206 to 220 of both of mouse and human DISC1 were crucial for binding with Htt 
(Figure 5A). Furthermore, in agreement with these observations from peptide arrays, mutant 
mouse DISC1 lacking amino acids 201-228 (Δ201-228-DISC1) displayed a dramatic reduction 
in DISC1-Htt513 binding in cells, compared with that in wild-type DISC1 (Supplemental 
Figure 7B). Importantly, this deletion showed minimal effects on DISC1-PDE4B1 and 
DISC1-PDE4B2 binding (Supplemental Figure 7B). Therefore, we expressed Δ201-228-DISC1 
in neuro2a cells carrying the mutant Htt fragment. We then observed a greater extent of blockade, 
or complete normalization, against aberrantly augmented PDE4 activity, compared to the effects 
of wild-type DISC1 (Supplemental Figure 7A).  
If aggregation of DISC1 is mediating the reduced PDE4 activity in HD brain, then the 
ectopic introduction of additional DISC1 should rescue the aberrant PDE4 activity seen in HD. 
Since our observations indicated that PDE4 activity was augmented in the striatum of 
8-week-old R6/2 mice (Figure 1A), we next introduced exogenous DISC1 into the striatum of 
the 2-week-old mice by stereotaxic injection of a lentiviral vector of DISC1 connected with a 
green fluorescent protein Venus via IRES (DISC1/Venus). We then collected the 
DISC1/Venus-expressing cells from the striatum of the mice at 8 weeks by flow cytometry and 
measured PDE4 activity. Expression of wild-type DISC1 significantly decreased the aberrant 
PDE4 activity in R6/2 mice (Figure 5B). Introduction of DISC1Δ201-228 led to an even greater 
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effect, which is consistent with the observations from the cell model (Figure 5B). These results 
support the notion that pathological augmentation of PDE4 activity in HD pathology may be 
predominantly mediated by the partial loss of DISC1 that regulates PDE4 activity. This process 
is determined by the sequestration of DISC1 from the Htt-DISC1-PDE4 ternary complex as a 
result of specifically preferred binding and co-aggregation between mutant Htt and DISC1. 
Significance of Htt-DISC1-PDE4 interactions on non-motor functions in R6/2 mice. 
Next, we examined the in vivo consequences of the disturbed DISC1-PDE4 interaction. We 
generated adeno-associated virus (AAV) encoding an N-terminal 1-316 amino acid fragment of 
mouse DISC1 which includes most of the binding sites for PDE4 but lacks the binding region for 
Htt (Δ201-228-nDISC1) (Supplemental Figure 8). We stereotaxically injected AAV encoding 
control EGFP or Δ201-228-nDISC1 that could interact with PDE4B isoforms but not Htt, into 
the striatum of 3-week-old R6/2 mice. We confirmed impairment of motor functions in R6/2, 
evident by deficits in rotarod performance and total distance in the open filed test (Figures 5C 
and Supplemental Figure 9). These behaviors were not affected by exogenous expression of 
Δ201-228-nDISC1 (Figures 5C and Supplemental Figure 9). By contrast, R6/2 mice showed a 
trend of spending less time in the center region of the open field test (Figure 5D). Although the 
difference was not statistically significant between R6/2 and wild-type mice, we took this change 
as an indication of anxiety-like manifestation (41, 42). Interestingly, the exogenous expression of 
Δ201-228-nDISC1, but not expression of a control protein EGFP, significantly altered the 
reduction of the center time and ameliorated the pathological behavior (Figure 5D). These 
results suggest the involvement of the DISC1-PDE4-Htt pathway specifically in the anxiety 
phenotype displayed by R6/2 mice. 
 
Discussion  
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Here we demonstrate that the sequestration of intrinsically amyloidogenic DISC1, but not PDE4, 
into mutant Htt aggregates disturbed the proper formation of a Htt-DISC1-PDE4 ternary protein 
complex. This generates a PDE4 fraction out of physiological control by DISC1, thereby 
aberrantly increasing PDE4 activity (Supplemental Figure 10). Furthermore, our exploratory 
study in vivo suggests that this molecular pathway may underlie anxiety-like manifestations in 
the R6/2 model. The proposed molecular mechanism may account for the effects of rolipram, a 
specific PDE4 inhibitor, which ameliorate the pathological phenotype in these animals (28, 29). 
Finally, we hypothesize that this mechanism provides a novel molecular basis for the pathology 
and potentially the psychiatric symptoms, underpinning the reduced cAMP levels observed in 
both HD patients and model mice (11, 12).  
We show here that the aggregation of DISC1 is significantly accelerated by the presence of 
mutant Htt aggregate seeds. Importantly, our structural analysis of DISC1 amyloid provided 
mechanistic insights into the efficient cross-seeding between mutant Htt and DISC1: the core 
region (residues 209-227) of DISC1 aggregates included the binding site for Htt (residues 
206-220). This overlap might increase the chance of interactions between aggregation-prone core 
regions in distinct DISC1 molecules and thereby facilitate the sequestration of DISC1 into 
mutant Htt aggregates. In addition, the increase in amyloidogenicity of DISC1 aggregates by 
cross-seeding with mutant Htt may enhance the resistance to degradation and promote further 
recruitment of soluble DISC1 into mutant Htt aggregates.  
The present report in cell biology and biophysics now provides at least two questions to be 
addressed in future studies. First, it will be important to clarify whether the sequestration of 
DISC1 into misfolded protein fractions and aggregates is specific to HD or more generally 
applied to other polyQ diseases. The present data from the R6/2 model that represents the polyQ 
pathology implies that DISC1 may also be involved in other polyQ diseases. Second, the next 
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study may use a full-length Htt mouse model to address the influence of Htt on broader aspects 
of HD pathology. 
Recent studies have indicated that brain samples from a subgroup of patients with 
schizophrenia, bipolar disorder, or depression contain insoluble DISC1 and dysbindin, another 
protein that might be involved in the biology of mental functions (25, 43). Taken together, we 
provocatively propose that a selective network of misfolded proteins that are prone to be 
insoluble may underlie many aspects of brain dysfunctions, including psychiatric manifestations.  
 
Methods 
Plasmids and antibodies.  The cDNA of full-length mouse DISC1 was subcloned into a pRK5 
vector with an HA or myc tag at the N-terminus or with a pcDNA4 vector (Invitrogen) with a 
mys/His6 tag at the C-terminus. The cDNA of full-length human PDE4B1, 4B2, or 4B3 was 
subcloned into a pRK5 vector with an N-terminal HA tag. The cDNA of Htt67 or Htt513 
containing 18 or 82 glutamine repeats was inserted into pCSII-CMV vector that includes EGFP 
at the C-terminus. For production of lentivirus, the cDNA of full-length or mutant mouse DISC1 
with a C-terminal HA tag was subcloned into a pCSII-CMV-IRES-Venus plasmid. pCSII-CMV, 
pCAG-HIVgp, and pCAG-VSV-G plasmids were provided by the RIKEN BioResource Center. 
For production of AAV, the cDNA of full-length or mutant mouse DISC1was subcloned into a 
pAAV2 vector. For bacterial expression of DISC1 and Htt67Q42, the cDNA of human DISC1, 
Htt513Q18 and Htt67Q42 was inserted into a pCold-TF (Takara), pMAL (NEB) and pGEX6P2 
(GE) vector including a His-tag at the C, N and N terminus, respectively. Rabbit polyclonal 
mouse DISC1 (m317C) and human DISC1 (h316C) antibodies were raised against the purified 
proteins of residues 317-852 in mouse DISC1 and residues 316-854 in human DISC1, 
respectively, in the Research Resources Center in RIKEN Brain Science Institute (Supplemental 
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Figure 2). A mouse monoclonal antibody for mouse DISC1 (M49) was produced with the 
purified protein of residues 317-852 as an antigen (MBL) (Supplemental Figure 2). The 
following commercial or published antibodies were also used: mouse monoclonal (Nacalai 
tesque) and rabbit polyclonal (MBL) antibodies for HA, myc and GFP tags, for mouse DISC1 
(mEx3) (44), (D27) (45) and (2B3) (46), for human DISC1 (hEx2) (47) and for Htt (EM48 and 
MAB2144, Millipore), a sheep polyclonal anti-pan PDE4B antibody (34) and a mouse 
monoclonal antibody for β-actin (Abcam). Mouse, rabbit or sheep IgG (Santa Cruz) was also 
used as a control in co-immunoprecipitation experiments.  
The R6/2 mice and autopsied brains from HD patients.  Heterozygous Htt67 
(corresponding to Htt exon 1) transgenic mice of R6/2 were obtained from Jackson Laboratory 
(Bar Harbor, ME) and maintained by ovarian transplantation of female R6/2 mice carrying about 
130 CAG repeats. R6/2 transgenic and age-matched wild-type mice were anesthesized and the 
brains were removed, followed by separation of cerebral cortex and striatum. For measurement 
of PDE4 activity, storage of brains at -80 oC was minimized.  
Measurement of PDE4 activity.  PDE4 activity was assayed by our reported protocol (48). 
Briefly, brains or cells were homogenized in KHEM buffer (50 mM KCl, 10 mM EGTA, 1.92 
mM MgCl2, 1 mM DTT, and 50 mM HEPES, pH 7.2) containing protease inhibitor cocktail 
(Roche Applied Sciences), centrifuged, and the supernatant fraction was used to measure the 
PDE4 activity. Total cAMP specific phosphodiesterase activity was measured with 1 µM/l 
cAMP substrate concentration by using a fluorescence polarization assay (Molecular Devices) 
under linear conditions with and without the PDE4 inhibitor, rolipram at a concentration known 
to fully and selectively inhibit PDE4 (10 µM) (49). 
Western blotting.  A standard protocol was used, including 5-20% gradient acrylamide 
gels (ATTO). For detection, appropriate peroxidase-conjugated secondary antibodies (GE 
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Healthcare) were used in conjunction with a Supersignal West pico or femto chemiluminescent 
substrate (Thermo Fisher) to obtain images with LAS3000 (GE Healthcare).  
Immunoprecipitation.  Typically, cells or brains were lysed with RIPA buffer [50 mM 
Tris, pH 7.4, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, and a protease 
inhibitor cocktail (Roche)]. Lysates were sonicated, cell debris was cleared by centrifugation at 
200 g for 3 min at 4 oC, and the soluble fraction was subjected to immunoprecipitation with a 
primary antibody or an appropriate IgG control with Dynabeads protein G (Invitrogen). Green 
fluorescent protein (GFP) or monomeric red fluorescent protein (mRFP) was used as a negative 
control of binding partner. For sequential immunoprecipitation studies, Crosslink Magnetic 
IP/Co-IP Kit (Pierce) was used according to the manufacturer’s protocol. The first and second 
immunoprecipitations were conducted with anti-DISC1 (m317C) and Htt (MAB2166) antibodies, 
respectively. An appropriate IgG was used as negative control for each reaction. For competitive 
binding experiments, lysates of the HEK293T cells overexpressing Htt513Q18-GFP or 
Htt513Q82-GFP were added to lysates of the HEK293T cells overexpressing DISC1-myc and 
PDE4B1-HA. The mixture was processed for immunoprecipitation with an anti-c-myc antibody.  
Sedimentation assay.  Samples (0.1 g) of cerebral cortex or striatum in wild-type or R6/2 
mice were homogenized with 1 mL of RIPA buffer [50 mM Tris, pH 7.4, 150 mM NaCl, 1% 
NP40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail (Roche)] by a 
digital homogenizer at 1,500 rpm for 15 strokes and sonicated for 10 sec (Branson sonifier, 
15%). The homogenates were partially cleared by centrifugation at 200 g for 3 min at 4 oC and 
the supernatant (total fraction) was further centrifuged at 16,000 g for 15 min at 4 oC. Protein 
concentration of the total and supernatant fractions was determined by a BCA assay kit (Thermo 
Fisher) and 60 µg of protein/well of the total and supernatant fractions were used for 
immunoblotting.  
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Filter trap assay.  Samples (0.1 g) of cerebral cortex or striatum in wild-type and R6/2 
mice, or human controls and HD patients were homogenized with 1 mL of PBS including a 
protease inhibitor cocktail (Roche) by a digital homogenizer at 1,500 rpm for 15 strokes and 
sonicated for 10 sec (Branson sonifier, 15%). The homogenates were cleared by centrifugation at 
200 g for 3 min at 4 oC and protein concentration of the supernatant (total fraction) was 
determined by a BCA assay kit (Thermo Fisher). 50 µg of protein/hole of the total brain 
homogenate was loaded onto a cellulose acetate membrane (0.2 µm, Advantec) in the dot blot 
apparatus (Bio-Rad) and the membrane was washed with 2% SDS, followed by immunoblotting. 
Loading of the same protein amounts on the membrane was confirmed by western blotting of the 
total fractions.  
Immunohistochemistry.  Mouse brains were fixed with 4% buffered paraformaldehyde, 
mounted with tissue mount (Shirai Kogyo), and frozen by carbon dioxide. The frozen brains 
were sectioned with a cryostat at 10 µm (Leica CM3050 S). Paraffin-embedded human brains 
were sectioned at 5 µm, followed by autoclaving in 10 mM citrate buffer, pH 6.0 at 121 oC for 3 
min. Immunostaining was performed with a primary antibody (1:100-500), followed by Alexa 
Fluor 488- or 546-conjugated secondary antibodies (1:300) (Invitrogen). Vectorshield mountaing 
medium with DAPI (Vector Labs) was used to stain the nucleus. Fluorescent images of the 
serial-cut frozen or paraffin sections were acquired with a confocal microscope FV-1000D 
(Olympus) or C2 (Nikon). 
Preparation of recombinant proteins and amyloid.  Expression and purification of 
HisGST-tagged Htt67Q42 were reported previously(36). DISC1 protein was expressed at 15 oC 
in E. coli. [BL21 (DE3) Rosetta] as a fusion protein with a Hisx7-tag and trigger factor (TF) 
from a pCold TF (Takara) vector and was purified with 50 mM Tris-HCl buffer, pH 8.0, with 1 
M NaCl and 2 mM β-mercaptoethanol under the native condition with Nickel agarose resin (GE 
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Healthcare). DISC1 protein was eluted with the same buffer containing 250 mM imidazole, 
concentrated, and passed through a 1000K filter (Millipore) to remove preexisting aggregates. 
Staining with Coomassie Brilliant Blue showed that DISC1 was >90% pure and the protein 
concentration was determined at an extinction coefficient of HisTF-DISC1 (85,600 mM-1cm-1). 
For amyloid formation, typically 1 mL of 5 µM protein solution with 10 units of turbo3C 
protease (Accelagen) to cleave the tag was rotated in an end-over-end manner in a 2-mL tube at 
37 oC (36).  
Characterization of DISC1 amyloid in vitro.  The presence of amyloid-like structures in 
DISC1 aggregates was examined by an amyloid-specific fluorescent dye, thioflavine T (Sigma). 
The fluorescence of thioflavine T (excitation, 442 nm; emission, 483 nm) in 50 mM Na-glycine 
buffer (pH 8.0) including 12.5 µM thioflavine T and 5 µM DISC1 aggregates was measured with 
a fluorescence plate reader (ARVO MX, PerkinElmer) (36). For morphological observation of 
DISC1 aggregates with transmission electron microscopy (JEM 1200EX, JEOL), an aliquot of 2 
µM DISC1 aggregates was adsorbed onto carbon-coated 400-mesh copper grids, followed by 2% 
paraformaldehyde and 2% glutaraldehyde in 100 mM sodium phosphate buffer. The samples 
were negatively stained with 2% sodium phosphotungstic acid. Far-UV CD and FT-IR spectra of 
DISC1 aggregates were measured as described previously (36, 50). A core region in DISC1 
aggregates was identified with a 4800 plus MALDI-TOF/TOF Analyzer (AB SCIEX) as 
previously reported (51). The kinetics of DISC1 aggregation was monitored by the absorbance 
(turbidity) at 405 nm, with 10 mM DISC1 protein in 5 mM potassium phosphate buffer 
containing 150 mM sodium chloride (pH 7.4), and 2 units of turbo3C protease in the absence or 
presence of seeds of indicated aggregates [10% (mol/mol)] with a plate reader in a 96-well 
format (SpectraMax M2, Molecular Devices). The aggregate seeds were prepared by sonication 
(Branson sonifier, 15%) of 5 mM protein aggregates for 10 sec. The plate reader instrument 
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agitates a 96-well plate for 5 sec every 2 min. A filter trap assay was performed with 10 mg of 
Htt67Q42, DISC1 or BSA aggregates by using a cellulose acetate membrane (0.2 mm, 
Advantec) in the dot blot apparatus (Bio-Rad). After the protein was loaded, the membrane was 
washed with 5 mM potassium phosphate buffer (pH 7.4) with 2% SDS, followed by detection of 
signals with Sypro Ruby staining (Bio-Rad). 
Peptide array.  MBP-Htt513Q18 protein was expressed at 20oC in E. coli. BL21 (DE3) 
Rosetta as a fusion protein with an N-terminal Hisx7-tag and purified as TF-DISC1. Coomassie 
Brilliant Blue staining showed that MBP-Htt513Q18 was >90% pure, and the protein 
concentration was determined by an extinction coefficient of MBP-Htt513Q18 (37,940 
mM-1cm-1). Peptide arrays of mouse and human DISC1 were generated as previously reported 
(19, 52, 53). 1 µg of MBP alone or MBP-Htt513Q18 protein in PBS was overlaid to the peptide 
array. The array was washed with PBS, followed by detection as previously reported (19, 53). 
Production of lentivirus and injection into mice.  HEK293T cells were transfected with a 
pCSII-CMV-mouse DISC1- or Δ201−228−DISC1-IRES-Venus plasmid together with 
pCAG-HIVgp and pCAG-VSV-G plasmids, and forskolin (Sigma) was added to the culture 
medium (10 µM). Purification of lentivirus was performed as previously reported (53), with the 
exception that the lentivirus was concentrated with Lenti-X Concentrator (Clontech) and the 
pellet was resuspended with MACS Neurobasal media (Miltenyi Biotec) containing MACS B27 
plus (Miltenyi Biotec), penicillin and streptomycin (Nacalai). Stereotaxic injections were 
bilaterally placed at 0 and 1.0 mm anterior to the bregma, 2.0 mm lateral to the sagittal suture, 
and 2.0 mm below the skull surface in 2 week-old wild-type or R6/2 mice. 1 µL of lentivirus 
(200 µL of lentivirus purified from 10 mL culture) was injected with the rate of 0.1 µL/min by a 
microinjector (Narishige). Immunohistochemical analyses with frozen sections of the mice 
confirmed the expression of Venus and DISC1 in striatum. At 8 weeks, the striatum of the mice 
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was removed, minced on ice and treated with a Papain Dissection System (Worthington) to 
separate cells. The cells were treated with propidium idodide (Nacalai), and the 
Venus-expressing and propidium iodide-negative cells were collected by flow cytometry 
(FACSAria, BD), followed by centrifugation at 1,000 g for 15 min at 4 oC.  
Behavioral analysis of mice.  Following injection of AAV in striatum, the behavioral tests 
were performed for wild-type and R6/2 mice at the age of 8-10 weeks. The open filed test was 
performed as previously described (54). Briefly, each mouse was placed in the center of the open 
field [50×50×40 (H) cm] and allowed to move freely for 15 min. Distance traveled (cm) and time 
spent (%) in the center area (30%) of the field or in the four corner squares of the 5×5 
subdivisions were measured every 1 min and analyzed by TimeOFCR4 (O'Hara & Co.). For the 
rotarod performance test, a mouse was placed on a rotating rod (Muromachi Kikai) and the 
latency time the mouse was able to run on the rod was measured. The speed of rotation on day 1 
was 4 rpm and was increased from 4 to 40 rpm over a 4-min period and then kept at 40 rpm for 
another 1 min from days 2 to 5. Mice were tested in one trial for 2 min on day 1 and in four trials 
with a maximum time of 300 sec (intervals between trials were 20–30 sec) on days 2 to 5. The 
latency time of mice on the rotating rod was recorded by the instrument. 
Statistical analysis.  For analyses of two groups, P-values were determined by t-test. For 
analyses of three or more groups, P-values were determined by one-way ANOVA followed by 
Bonferroni post hoc corrections. The P values of <0.05 (*), <0.01 (**), and <0.001 (***) were 
considered to be statistically significant. 
Study approval.  All of the animal experiments were performed in compliance with 
relevant laws and guidelines issued by RIKEN and JHU. Samples of autopsied brains were 
obtained from the Harvard Brain Tissue Resource Center at McLean Hospital in Belmont, 
Massachusetts.
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Figure legends 
Figure 1. PDE4 activity could be regulated by the newly identified Htt-DISC1-PDE4 
ternary protein complex.  
(A) PDE4 activities of the homogenates of cerebral cortex (left) and striatum (right) in R6/2 mice 
were increased compared with those in wild-type (WT) at 8 and 12 weeks of age. Error bars 
denote S.E.M. *P<0.05, **P<0.01, ***P<0.001.  
(B) Protein complex of Htt-DISC1-PDE4B in cerebral cortex of wild-type mice. Brain 
homogenates were immunoprecipitated by an anti-DISC1 (mEx3), anti-PDE4B (pan PDE4B), or 
anti-Htt (MAB2144) antibody or IgG control, followed by immunoblotting with an anti-Htt 
(MAB2144), anti-DISC1 (D27) or anti-PDE4B (pan PDE4B) antibody.  
(C) Formation of Htt-DISC1-PDE4B tertiary protein complex in cerebral cortex of wild-type 
mice was detected with sequential co-immunoprecipitation. Brain homogenates were 
immunoprecipitated by an anti-DISC1 (m317C) (1st IP) then the immunoprecipitates were 
immunoprecipitated by Htt antibody (MAB2166) (2nd IP), followed by immunoblotting with an 
anti-Htt (MAB2166), anti-DISC1 (2B3) or anti-PDE4B (pan PDE4B) antibody. Negative control 
was immunoprecipitated by IgG. 
(D) Increased binding of Htt513 and DISC1 with expansion of polyQ in HEK293T cells by 
co-immunoprecipitation. Error bars denote S.E.M. *P<0.05.  
(E) Increased binding of Htt67 and DISC1 with expansion of polyQ in HEK293T cells by 
co-immunoprecipitation. Error bars denote S.E.M. ***P<0.001.  
 
Figure 2. DISC1, but not PDE4B, is sequestered into insoluble Htt aggregates in HD. 
(A) Filter trap assay with homogenates of cerebral cortex or striatum from 12-week-old R6/2 
mice showed significantly increased levels of Htt (EM48) (top) and DISC1 (mEx3) (middle), but 
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not PDE4B (pan PDE4B) (bottom) in the SDS-resistant fraction, compared with those from 
wild-type (WT) mice. Error bars denote S.E.M. *P<0.05, **P<0.01.  
(B) Filter trap assay with homogenates of cerebral cortex or striatum showed significantly 
increased levels of Htt (EM48) (top) and DISC1 (h2p) (middle), but not PDE4B (pan PDE4B) 
(bottom) in the SDS-resistant fraction from HD patients (HD), compared to those from controls 
(Con). Error bars denote S.E.M. *P<0.05, ***P<0.001. 
(C) Immunostaining of frozen sections of cerebral cortex (left) or striatum (right) demonstrated 
that DISC1 was colocalized with intranuclear inclusions of mutant Htt in 12-week-old R6/2 mice. 
Green, Htt (EM48); red, DISC1 (m317C); blue, DAPI (the nucleus). Arrowheads show 
intranuclear inclusions. Scale bar, 10 µm. 
(D) Immunostaining of paraffin sections of cerebral cortex (left half) or striatum (right half) in 
HD patients (HD) and human controls (Con) was performed with anti-Htt (EM48) (green, left) 
and anti-DISC1 (h316C) (red) antibodies. Nucleus was stained by DAPI (blue). Merged images 
are shown on the right. Arrowheads show intranuclear inclusions. Scale bar, 10 µm.  
 
Figure 3. Aggregation of intrinsically amyloidogenic DISC1 is accelerated by cross-seeding 
with polyQ-expanded mutant Htt. 
(A) Thioflavin T (ThT) fluorescent intensities of DISC1 and Htt67Q42 aggregates were 
significantly higher than that of BSA aggregates. Error bars denote S.E.M. ***P<0.001.  
(B) Fibrillar morphology of typical DISC1 amyloid shown by transmission electron microscopy. 
Scale bar, 100 nm.  
(C) MALDI-TOF mass spectrum of DISC1 aggregates digested by proteinase K indentified a 
major mass peak at 2012.9 m/Z corresponding to residues 209-227 in DISC1 as the core of 
DISC1 aggregates.  
30 
 
(D) Aggregation of DISC1, which was monitored by the absorbance (turbidity) at 405 nm, was 
significantly accelerated by the Htt67Q42 aggregate seeds but not by BSA aggregates.  
(E) FT-IR spectra revealed that the DISC1 aggregates formed in the presence of Htt67Q42 
aggregate seeds (grey) contained more intermolecular β-sheet structures (arrowheads) than did 
spontaneously formed DISC1 aggregates (black).  
(F) The DISC1 aggregates formed in the presence of Htt67Q42 aggregate seeds showed higher 
resistance to 2% SDS than spontaneously formed DISC1 aggregates in the filter trap assay with 
Sypro Ruby staining. Error bars denote S.E.M. 
 
Figure 4. DISC1-PDE4 interactions are reduced by decreased soluble DISC1 levels in the 
R6/2 mice. 
(A) Soluble DISC1, but not soluble PDE4B levels in supernatant fractions (Sup) were reduced in 
cerebral cortex (top) and striatum (bottom) from 12-week-old R6/2 mice, compared to those 
from wild-type (WT) mice. Total DISC1 and PDE4B levels in total homogenates (Total) were 
not changed between WT and R6/2 mice. β-actin is a loading control. DISC1 antibodies (mEx3 
for cortex, m317C for striatum) were used for immunblotting. Error bars denote S.E.M. *P<0.05.  
(B) Binding between PDE4B and DISC1 in 12-week-old R6/2 mouse brains was decreased 
compared to that of wild-type (WT) brains. Immunoprecitation was performed by an anti-pan 
PDE4B antibody, followed by immunoblotting with anti-DISC1 antibody (D27). Error bars 
denote S.E.M. **P<0.01.  
(C) Exogenous addition of Htt513Q82, but not Htt513Q18, significantly reduced DISC1-PDE4B 
interactions in HEK293T cells. Lysates of the cells overexpressing GFP alone (−), 
Htt513Q18-GFP (Q18), or Htt513Q82-GFP (Q82) were added to lysates of the cells 
overexpressing DISC1-myc and PDE4B1-HA. Mixtures were processed for immunoprecipitation 
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with an anti-c-myc antibody, followed by immunoblotting. Error bars denote S.E.M. *P<0.05, 
**P<0.01. 
 
Figure 5. Aberrantly enhanced PDE4 activity and anxiety levels in the R6/2 mice are 
recovered by exogenous DISC1 expression. 
(A) The 25mer-peptides #40-#42 [residues 194-228 for mouse DISC1 (left), residues 196-230 
for human DISC1 (right)] in DISC1 showed binding to maltose binding protein 
(MBP)-Htt513Q18 (bottom) but not MBP alone (top) on peptide array. A black line corresponds 
to the amyloid core region identified by limited proteolysis and mass spectrometry (see Figure 
3C).  
(B) Aberrant augmentation of PDE4 activity in striatum of R6/2 mice was normalized with Wt or 
Δ201-228-DISC1. Error bars denote S.E.M. *P<0.05, **P<0.01.  
(C) The locomotor activity of R6/2 mice was not affected by expression of Δ201-228-nDISC1. 
Total distance moved in the open field test was measured in mice at 8 weeks. Error bars denote 
S.E.M. n=15, 15, 18, 17 for WT+EGFP, WT+Δ201-228-nDISC1, R6/2+EGFP, 
R6/2+Δ201-228-nDISC1 mice, respectively. **P<0.01, ***P<0.001.  
(D) The anxiety levels in R6/2 mice were reduced by expression of Δ201-228-nDISC1. The time 
spent in a center region in the open field test was measured in mice at 8 weeks. Error bars denote 
S.E.M. n=15, 15, 18, 17 for WT+EGFP, WT+Δ201-228-nDISC1, R6/2+EGFP, 
R6/2+Δ201-228-nDISC1 mice, respectively. *P<0.05.  
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Figure 1. PDE4 activity could be regulated by the newly identified Htt-DISC1-PDE4 ternary protein 
complex. 
(A) PDE4 activities of the homogenates of cerebral cortex (left) and striatum (right) in R6/2 mice were 
increased compared with those in wild-type (WT) at 8 and 12 weeks of age. Error bars denote S.E.M. 
*P<0.05, **P<0.01, ***P<0.001. 
(B) Protein complex of Htt-DISC1-PDE4B in cerebral cortex of wild-type mice. Brain homogenates were 
immunoprecipitated by an anti-DISC1 (mEx3), anti-PDE4B (pan PDE4B), or anti-Htt (MAB2144) antibody or 
IgG control, followed by immunoblotting with an anti-Htt (MAB2144), anti-DISC1 (D27) or anti-PDE4B 
(pan PDE4B) antibody. 
(C) Formation of Htt-DISC1-PDE4B tertiary protein complex in cerebral cortex of wild-type mice was 
detected with sequential co-immunoprecipitation. Brain homogenates were immunoprecipitated by an 
anti-DISC1 (m317C) (1st IP) then the immunoprecipitates were immunoprecipitated by Htt antibody 
(MAB2166) (2nd IP), followed by immunoblotting with an anti-Htt (MAB2166), anti-DISC1 (2B3) or 
anti-PDE4B (pan PDE4B) antibody. Negative control was immunoprecipitated by IgG.
(D) Increased binding of Htt513 and DISC1 with expansion of polyQ in HEK293T cells by 
co-immunoprecipitation. Error bars denote S.E.M. *P<0.05. 
(E) Increased binding of Htt67 and DISC1 with expansion of polyQ in HEK293T cells by 
co-immunoprecipitation. Error bars denote S.E.M. ***P<0.001. 
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Figure 2. DISC1, but not PDE4B, is sequestered into insoluble Htt aggregates in HD.
(A) Filter trap assay with homogenates of cerebral cortex or striatum from 12-week-old R6/2 mice showed 
significantly increased levels of Htt (EM48) (top) and DISC1 (mEx3) (middle), but not PDE4B (pan PDE4B) 
(bottom) in the SDS-resistant fraction, compared with those from wild-type (WT) mice. Error bars denote 
S.E.M. *P<0.05, **P<0.01. 
(B) Filter trap assay with homogenates of cerebral cortex or striatum showed significantly increased levels 
of Htt (EM48) (top) and DISC1 (h2p) (middle), but not PDE4B (pan PDE4B) (bottom) in the SDS-resistant 
fraction from HD patients (HD), compared to those from controls (Con). Error bars denote S.E.M. *P<0.05, 
***P<0.001.
(C) Immunostaining of frozen sections of cerebral cortex (left) or striatum (right) demonstrated that DISC1 
was colocalized with intranuclear inclusions of mutant Htt in 12-week-old R6/2 mice. Green, Htt (EM48); 
red, DISC1 (m317C); blue, DAPI (the nucleus). Arrowheads show intranuclear inclusions. Scale bar, 10 μm.
(D) Immunostaining of paraffin sections of cerebral cortex (left half) or striatum (right half) in HD patients 
(HD) and human controls (Con) was performed with anti-Htt (EM48) (green, left) and anti-DISC1 (h316C) 
(red) antibodies. Nucleus was stained by DAPI (blue). Merged images are shown on the right. Arrowheads 
show intranuclear inclusions. Scale bar, 10 μm.
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Figure 3. Aggregation of intrinsically amyloidogenic DISC1 is accelerated by cross-seeding with 
polyQ-expanded mutant Htt.
(A) Thioflavin T (ThT) fluorescent intensities of DISC1 and Htt67Q42 aggregates were significantly higher 
than that of BSA aggregates. Error bars denote S.E.M. ***P<0.001. 
(B) Fibrillar morphology of typical DISC1 amyloid shown by transmission electron microscopy. 
Scale bar, 100 nm. 
(C) MALDI-TOF mass spectrum of DISC1 aggregates digested by proteinase K indentified a major mass 
peak at 2012.9 m/Z corresponding to residues 209-227 in DISC1 as the core of DISC1 aggregates. 
(D) Aggregation of DISC1, which was monitored by the absorbance (turbidity) at 405 nm, was significantly 
accelerated by the Htt67Q42 aggregate seeds but not by BSA aggregates. 
(E) FT-IR spectra revealed that the DISC1 aggregates formed in the presence of Htt67Q42 aggregate 
seeds (grey) contained more intermolecular β-sheet structures (arrowheads) than did spontaneously 
formed DISC1 aggregates (black). 
(F) The DISC1 aggregates formed in the presence of Htt67Q42 aggregate seeds showed higher resistance 
to 2% SDS than spontaneously formed DISC1 aggregates in the filter trap assay with Sypro Ruby staining. 
Error bars denote S.E.M.
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Figure 4. DISC1-PDE4 interactions are reduced by decreased soluble DISC1 levels in the R6/2 mice.
(A) Soluble DISC1, but not soluble PDE4B levels in supernatant fractions (Sup) were reduced in cerebral 
cortex (top) and striatum (bottom) from 12-week-old R6/2 mice, compared to those from wild-type (WT) 
mice. Total DISC1 and PDE4B levels in total homogenates (Total) were not changed between WT and 
R6/2 mice. β-actin is a loading control. DISC1 antibodies (mEx3 for cortex, m317C for striatum) were 
used for immunblotting. Error bars denote S.E.M. *P<0.05. 
(B) Binding between PDE4B and DISC1 in 12-week-old R6/2 mouse brains was decreased compared to 
that of wild-type (WT) brains. Immunoprecitation was performed by an anti-pan PDE4B antibody, 
followed by immunoblotting with anti-DISC1 antibody (D27). Error bars denote S.E.M. **P<0.01. 
(C) Exogenous addition of Htt513Q82, but not Htt513Q18, significantly reduced DISC1-PDE4B 
interactions in HEK293T cells. Lysates of the cells overexpressing GFP alone (−), Htt513Q18-GFP (Q18), 
or Htt513Q82-GFP (Q82) were added to lysates of the cells overexpressing DISC1-myc and PDE4B1-HA. 
Mixtures were processed for immunoprecipitation with an anti-c-myc antibody, followed by immunoblotting. 
Error bars denote S.E.M. *P<0.05, **P<0.01.
Figure 4
Figure 5
B
WT R6/2
+
Control
R6/2
+
Wt
-DISC1
R6/2
+
Δ201-228
-DISC1
P
D
E
4 
ac
tiv
ity
 (A
.U
.)
**
**
*
0
2
1
3
4
5
WT
+
eGFP
WT
+
Δ201-228
-nDISC1
C
EGFP
R6/2
+
R6/2
+
Δ 201-228
-nDISC1
To
ta
l d
is
ta
nc
e 
(c
m
)
C
en
te
r r
eg
io
n 
(%
)
0
8000
4000
D
**
***
*
0
50
25
WT
+
eGFP
WT
+
Δ201-228
-nDISC1
R6/2
+
EGFP
R6/2
+
Δ201-228
-nDISC1
Striatum 
Mouse DISC1
39  40   41   42   43
MBP
MBP-Htt513Q18
Array #
40 ADIASLPGFQDTFTSSFSFIQLSLG
           #41 LPGFQDTFTSSFSFIQLSLGAAGER
                       #42 DTFTSSFSFIQLSLGAAGERGEAEG
Array #
Human DISC1
38 39 40 41 42 43 44 45 46
MBP
MBP-Htt513Q18
Array #40 PPTPPGSHSAFTSSFSFIRLSLGSA
Array #
       #41 GSHSAFTSSFSFIRLSLGSAGERGE
        #42 FTSSFSFIRLSLGSAGERGEAEGCP
206 220206 220
A
Figure 5. Aberrantly enhanced PDE4 activity and anxiety levels in the R6/2 mice are recovered by 
exogenous DISC1 expression.
(A) The 25mer-peptides #40-#42 [residues 194-228 for mouse DISC1 (left), residues 196-230 for human 
DISC1 (right)] in DISC1 showed binding to maltose binding protein (MBP)-Htt513Q18 (bottom) but not 
MBP alone (top) on peptide array. A black line corresponds to the amyloid core region identified by limited 
proteolysis and mass spectrometry (see Figure 3C). 
(B) Aberrant augmentation of PDE4 activity in striatum of R6/2 mice was normalized with Wt or 
Δ201-228-DISC1. Error bars denote S.E.M. *P<0.05, **P<0.01. 
(C) The locomotor activity of R6/2 mice was not affected by expression of Δ201-228-nDISC1. Total distance 
moved in the open field test was measured in mice at 8 weeks. Error bars denote S.E.M. n=15, 15, 18, 17 
for WT+EGFP, WT+Δ201-228-nDISC1, R6/2+EGFP, R6/2+Δ201-228-nDISC1 mice, respectively. **P<0.01, 
***P<0.001. 
(D) The anxiety levels in R6/2 mice were reduced by expression of Δ201-228-nDISC1. The time spent in a 
center region in the open field test was measured in mice at 8 weeks. Error bars denote S.E.M. n=15, 15, 18, 
17 for WT+EGFP, WT+Δ201-228-nDISC1, R6/2+EGFP, R6/2+Δ201-228-nDISC1 mice, respectively. *P<0.05.
